Omnitura Therapeutics is a biopharmaceutical company engaged in the commercialization Multifunctional Multitargeted (MFMT™) pharmaceuticals for oncology, a new class of therapies (patents pending) that are designed to address the fundamentally complex and heterogeneous nature of cancer.
Omnitura's lead oncology product, Aneustat™ (OMN54), has received regulatory approval to commence clinical trials and shows great potential for treating many solid tumor cancers.
Aneustat represents a new class of multivalent cancer therapy and was formulated with the initial intent to treat lung and prostate cancer. Pre-clinical in vivo studies demonstrated that Aneustat inhibits tumor growth on par with chemotherapy combinations, but with no apparent side effects. With such an attractive safety profile, Aneustat is poised ultimately for ubiquitous use, including use as an adjuvant to surgery, radiation therapy, chemotherapy, and for maintenance (recurrence prevention) for many tumor types.
Aneustat's MFMT profile includes pro-apoptotic and antiangiogenic activity that has been observed in vitro and in vivo.